Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis

Company Overview

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Key Stats

• Today's Range: $1.51 to $1.58
• 50-Day Range: $1.32 to $3.59
• 52-Week Range: $1.02 to $59.40
• Volume: 11,208 shs
• Average Volume: 391,028 shs
• Market Capitalization: $3.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Biodexa Pharmaceuticals Stock Analysis - MarketRank™

Biodexa Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biodexa Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Biodexa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Biodexa Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.50% of the float of Biodexa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Biodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodexa Pharmaceuticals has recently decreased by 85.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biodexa Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Biodexa Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.

Percentage Held by Institutions

17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 9/10/2020
• Today: 8/11/2026
• Next Earnings (Estimated): 9/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BDRX
• Previous Symbol: LON:MTPH
• CIK: 1643918
• Web: www.midatechpharma.com
• Phone: 441235888300
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.03
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $470 thousand
• Price / Sales: 6.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $110.30 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 2,000,000
• Free Float: 1,989,000
• Market Cap: $3.09 million
• Optionable: Not Optionable
• Beta: 1.24